News | January 25, 2010

Direct Carotid Stenting Not Inferior to Predilation

January 25, 2010 – Direct stenting of the carotid arteries is a feasible technique and is not inferior to predilation, according to a new study published in the International Journal of Cardiology (Feb. 4, 2010, vol. 138, issue 3, pages 233-238).

A controversial aspect of carotid artery stenting (CAS) is the placement of a stent with or without predilation. The study was designed to test the hypothesis that direct stenting (DS) was not inferior to CAS with predilation. The stud was conducted by researchers at the Institute of Cardiology, University of Milan, Centro Cardiologico Monzino, Milan, Italy.

Elective CAS with filter protection was performed in 205 consecutive, unselected patients with carotid artery stenosis (more than 50 percent if symptomatic and equal to or more than 75 percent if asymptomatic by Doppler assessment) who were randomly assigned to CAS with predilation (n=100) or direct stenting (DS, n=105). Filter and stent selection were left to the operator's discretion. The study end-point was the angiographic success, defined as less than or equal to 30 percent angiographic residual stenosis after CAS without abnormal angiographic findings in cerebral circulation, and without cross-over to predilation in the DS group.

At baseline, patient clinical characteristics and stenosis anatomic features did not differ between groups. Angiographic success was 99 percent in predilation and 97 percent in DS. No cross-over to predilation occurred in the DS group. Procedural time was shorter in DS as compared to predilation (about 24.3 minutes versus about 19.9 minutes). Visible debris were more frequently captured in predilation as compared to DS (50 versus 36 percent).

No periprocedural and 30-day death or major stroke occurred in either group.

For more information: www.internationaljournalofcardiology.com


Related Content

News | Cardiovascular Clinical Studies

May 1, 2024 β€” A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 β€” Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 β€”Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 β€” Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 β€” CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
Subscribe Now